These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: Endoscopic bilateral metal stent placement for advanced hilar cholangiocarcinoma: a pilot study of a newly designed Y stent.
    Author: Lee JH, Kang DH, Kim JY, Lee SM, Kim DH, Park CW, Cho HS, Kim GH, Kim TO, Heo J, Song GA, Cho M, Kim S, Kim CW, Lee JW.
    Journal: Gastrointest Endosc; 2007 Aug; 66(2):364-9. PubMed ID: 17643714.
    Abstract:
    BACKGROUND: Although endoscopic stent placement is now generally accepted as a palliative method of treatment in unresectable hilar cholangiocarcinoma, exclusively endoscopic placement of bilateral metal stents has been considered very difficult and complex. OBJECTIVE: To evaluate the technical and clinical efficacy of endoscopic placement of dual, newly designed stents in a Y configuration. DESIGN: Prospective, uncontrolled, single center. SETTING: Tertiary referral university hospital. PATIENTS: Ten patients with unresectable hilar cholangiocarcinoma of Bismuth type II or higher. INTERVENTIONS: For bilateral metal stent placement, a biliary Y stent with central wide-open mesh was used exclusively at first. A second stent was placed into the contralateral hepatic duct through the central open mesh of the Y stent. MAIN OUTCOME MEASUREMENT: Technical success, functional success, early complications, and short-term clinical outcome. RESULTS: Technical success was achieved in 8 of 10 patients (80%). Among 8 patients in whom bilateral stents were successfully placed by endoscopy, functional success was 100%, the early complication rate was 0%, and the stent occlusion rate was 25%. The median stent patency period was 217 days. LIMITATIONS: Small number of patients, uncontrolled study, short-term follow-up period. CONCLUSIONS: We described a technique for endoscopic bilateral metal stent placement by using the newly designed Y stent for advanced hilar cholangiocarcinoma that resulted in a high success rate of 80%.
    [Abstract] [Full Text] [Related] [New Search]